research Upadacitinib for Alopecia: Current Evidence and Clinical Insights
Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
Search
for
Sort by
Research
510-540 / 1000+ results
research 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
Biologics and JAK inhibitors may improve treatment for scarring alopecias.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
EGFR-TKIs can cause significant skin, nail, and organ side effects.
research A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System
JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research LAM/TSC Cell Migration to Uterus in an Experimental Model of Lymphangioleiomyomatosis. Regulation by Anti-Epidermal Growth Factor Receptor Antibody and Rapamycin
Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
research ACKR2 limits skin fibrosis and hair loss through IFN‐β
ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research Systemic Therapies for Scarring and Non-scarring Alopecia
JAK inhibitors are effective for hair regrowth in severe alopecia areata.
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
research Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Discovery of novel 5α-reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations
A new compound may treat benign prostatic hyperplasia better than finasteride.
research Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
These new skin treatments are safer and more effective with minimal side effects.
research Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport
Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
research The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.